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EASL and AASLD guidelinesTo the Editor:
We read with interest the recent EASL Clinical Prac-
tice Guidelines on management of cholestatic liver dis-
ease [1]. We would like to congratulate the authors on
the correct grading of evidence for the use of ursodeoxy-
cholic acid (UDCA) in patients with primary biliary cir-
rhosis (PBC) but at the same time we would like to
challenge them about the interpretation of data.
Levels of evidence are designed as objective tools
based on widely accepted deﬁned criteria. The authors
correctly used a grade II-2/B1 recommendation for use
of UDCA in PBC, as data to support this are only avail-
able from “cohort or case–control analytical studies”. In
contrast, the recent AASLD clinical practice guidelines
[2] give a diﬀerent level of evidence for use of UDCA,
which is Class I, level A i.e. data to support this are
“derived from multiple randomized clinical trials or
meta-analyses”. This grading is methodologically incor-
rect and probably reﬂects opinion rather than evidence.
In fact, no single randomized controlled trial to date has
demonstrated a signiﬁcant eﬀect of UDCA in terms of
survival or liver transplantation, and neither have a
meta-analysis nor a Cochrane review, which evaluated
all randomized trials [3,4].
Although the authors of the EASL guidelines criticize
the published meta-analyses [3,4] for including studieswith short duration or with use of inadequate doses of
UDCA, this criticism is not justiﬁed. The Cochrane re-
view with updated and longer follow-up data still failed
to ﬁnd beneﬁt of UDCA [3], and sensitivity analyses
regarding UDCA dose in both meta-analyses showed
no diﬀerence between standard doses (>13 mg/kg) ver-
sus lower doses with respect to major outcome measures
[3,4]. Even a selective analysis of raw data from the
French, Canadian and Mayo cohorts showed a possible
beneﬁt of UDCA only in patients with moderate and se-
vere disease [5], in whom currently even those clinicians
who feel UDCA is eﬀective, acknowledge that it is less
likely to exert a beneﬁcial therapeutic eﬀect.
As regards the interpretation of evidence, the crucial is-
sue is the fact that in those studies in which cross-over
from placebo or no treatment to UDCA occurred, (after
approximately 2 years) the cross-over patients deterio-
rated despite using UDCA [4]. A potential solution to
evaluate this paradox was given in correspondence from
us [6]. Nevertheless, our suggestions for analysis have
never been taken up. However, we acknowledge that in
early stage and/or asymptomatic PBC, UDCAmay have
beneﬁt – but conclusive evidence is lacking. Data to sup-
port the use of UDCA in early asymptomatic PBC needs
strengthening. Indeed, the “Paris” and “Barcelona” crite-
ria mentioned by the authors, refer to cohorts with no
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madewith great caution [1]. In the asymptomatic PBC co-
hort described by Prince et al. (only 7% of patients were
takingUDCA), 45%did not develop a liver-related symp-
tom during a median follow-up of 7.4 years [7]. These
could be the same patients who “respond” to UDCA.
Moreover, the emphasis in the guidelines for evidence
of histological improvement is misplaced, as we have
previously pointed out [8]. Notably, in the original trials
there were patients in the non-ﬁbrotic stages of PBC
progressing to ﬁbrosis, despite an improvement in
inﬂammation [3,4]. This dichotomy between improve-
ment in inﬂammation but worsening of ﬁbrosis is diﬃ-
cult to interpret as an improvement in histological stage.
In conclusion, the absence of best-level evidence con-
ﬁrms that UDCA for all PBC patients remains an unre-
solved issue. Currently, the highest level of evidence
(meta-analysis of randomized trials) suggests that
UDCA does not inﬂuence patients’ survival, time to
transplantation, or any other patient-important clinical
outcome [3,4].
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We thank Dr. Tsochatzis et al. for their comments. In
the EASL Clinical Practice Guidelines (CPG), we
discussed in detail relevant data available to provide a
balanced discussion of the pro’s and con’s of ursodeoxy-
cholic acid (UDCA) treatment in primary biliary cirrho-
sis (PBC) [1]. Tsochatzis et al. address the diﬃculty of
ﬁnding a long-term beneﬁt of medical treatment particu-
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also in this subgroup. Therefore, the data presented from
the most recent studies of cohorts followed for a period
of at least a decade [3–5] appeared of value to us when
we recommended medical treatment of early-stage dis-
ease with UDCA [1].
A careful analysis of the available data deriving
from randomized controlled trials of high-quality suggest
that also in early-stage PBC, UDCA led not only to
improvement of biochemicalmarkers including surrogate
markers of survival, but also halted progression of histo-
logical stage. The Spanish randomized, placebo-con-
trolled multicenter trial was the ﬁrst large high-quality
study which addressed this issue by including only pa-
tients with stage 1–3 disease [6] and carefully following
them over a median period of 3.4 years to guarantee
adequate compliance (a factor which often receives inad-
equate attention and deserves consideration when dis-
cussing the dichotomy of short-term improvement of
biochemical markers and inﬂammation, but worsening
